{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:36:54Z","timestamp":1783532214432,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>We aim to review the most recent findings in the use of NK cells in childhood cancers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>Natural killer cells are cytotoxic to tumor cells. In pediatric leukemias, adoptive transfer of NK cells can bridge children not in remission to transplant. Interleukins (IL2, IL15) can enhance NK cell function. NK cell-CAR therapy has advantages of shorter life span that lessens chronic toxicities, lower risk of graft versus host disease when using allogeneic cells, ability of NK cells to recognize tumor cells that have downregulated MHC to escape T cells, and possibly less likelihood of cytokine storm. Cytotoxicity to solid tumors (rhabdomyosarcoma, Ewing\u2019s sarcoma, neuroblastoma) is seen with graft versus tumor effect in transplant and in combination with antibodies. Challenges lie in the microenvironment which is suppressive for NK cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>NK cell immunotherapy in childhood cancers is promising and recent works aim to overcome challenges.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11912-019-0837-8","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T02:03:31Z","timestamp":1568081011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers"],"prefix":"10.1007","volume":"21","author":[{"given":"Miriam Santiago","family":"Kimpo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernice","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"key":"837_CR1","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"L Yu Alice","year":"2010","unstructured":"Yu Alice L, Gilman AL, Ozkyanak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 Antibody , GM CSF, Interkleukin 2 and Isotretinoin for Neuroblastoma. N Engl J Med. 2010;363:1324\u201334.","journal-title":"N Engl J Med"},{"issue":"26","key":"837_CR2","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1182\/blood-2015-12-629055","volume":"127","author":"H Rupert","year":"2016","unstructured":"Rupert H, Lang P, Andre MC. Exploitation of natural killer cells for the treatment of acute leukemia. Blood. 2016;127(26):3341\u20139.","journal-title":"Blood"},{"key":"837_CR3","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1182\/blood-2014-05-572065","volume":"124","author":"F Babor","year":"2014","unstructured":"Babor F, Manser AR, Fischer JC, Scherenschlich N, Enczmann J, Chazara O, et al. KIR ligand C2 is associated with increased susceptibility to childhood ALL and confers an elevated risk for late relapse. Blood. 2014;124:2248\u201351. https:\/\/doi.org\/10.1182\/blood-2014-05-572065 .","journal-title":"Blood"},{"key":"837_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","volume":"18","author":"C Laura","year":"2018","unstructured":"\u2022 Laura C, Dumos PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18:671. https:\/\/doi.org\/10.1038\/s41577-018-0061-z . This review provides an update on the recognized group of innate lymphoid cells of which natural killer cells are part of and their role in immune oncology.","journal-title":"Nat Rev Immunol"},{"key":"837_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nri.2015.9","volume":"16","author":"C Adelheid","year":"2016","unstructured":"\u2022 Adelheid C, Lancer LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol. 2016;16:112. https:\/\/doi.org\/10.1038\/nri.2015.9 . This paper identifies NK cells as having memory, a characteristic associated with adaptive immunity.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"837_CR6","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1182\/blood-2010-10-313791","volume":"118","author":"Z Almalte","year":"2011","unstructured":"Almalte Z, Samarani S, Iannello A, Debbeche O, Duval M, Infante-Rivard C. Et. Al. novel associations between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia. Blood. 2011;118(5):1323\u20138.","journal-title":"Blood"},{"issue":"12","key":"837_CR7","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/sj.leu.2403525","volume":"18","author":"S Verheyden","year":"2004","unstructured":"Verheyden S, Bernier M, Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia. 2004;18(12):2002\u20137. https:\/\/doi.org\/10.1038\/sj.leu.2403525 .","journal-title":"Leukemia"},{"key":"837_CR8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.bbmt.2014.03.007","volume":"20","author":"J Rueff","year":"2014","unstructured":"Rueff J, Medinger M, Heim D, Passweg J, Stern M. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Biol Blood Marrow Transplant. 2014;20:896\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"837_CR9","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097\u2013100.","journal-title":"Science"},{"issue":"9","key":"837_CR10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ni.3518","volume":"17","author":"C Guillerey","year":"2016","unstructured":"Guillerey C, Huntington ND, Smyth MK. Targetting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025\u201336.","journal-title":"Nat Immunol"},{"key":"837_CR11","doi-asserted-by":"crossref","unstructured":"Schlegel P, Ditthard K, Lang P, et al. NKGD2 Signalling leads to NK cell mediated lysis of childhood AML. J Immunol Res. 2015;473175.","DOI":"10.1155\/2015\/473175"},{"key":"837_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/473175","volume":"4731","author":"P Schlegel","year":"2015","unstructured":"Schlegel P, Ditthard K, Lang P, Mezger M, Michaelis S, Handgretinger R, et al. NKG2D signaling leads to NK cell mediated lysis of childhood AML. J Immunol Res. 2015;4731:1\u201310. https:\/\/doi.org\/10.1155\/2015\/473175 .","journal-title":"J Immunol Res"},{"issue":"1","key":"837_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.4049\/jimmunol.172.1.644","volume":"172","author":"L Wing","year":"2004","unstructured":"Wing L, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172(1):644\u201350.","journal-title":"J Immunol"},{"issue":"26","key":"837_CR14","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1182\/blood-2014-05-572743","volume":"124","author":"A K\u00fcbler","year":"2014","unstructured":"K\u00fcbler A, Woiterski J, Witte KE, et al. Both mature KIR+ and immature KIR- NK cells control pediatric acute B-cell precursor leukemia in NOD. Gc-Prkdscid IL2rgtmWj\/Sz mice. Blood. 2014;124(26):3914\u201323.","journal-title":"Blood"},{"issue":"8","key":"837_CR15","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, SA MN, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051\u20137.","journal-title":"Blood"},{"issue":"6","key":"837_CR16","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","volume":"28","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W. J Clin Oncol. 2010;28(6):955\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"837_CR17","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/bmt.2009.265","volume":"45","author":"G Pittari","year":"2010","unstructured":"Pittari G, Fregni G, Roguet L, et al. Early evaluation of natural killer activity in posttransplant acute myeloid leukemia patients. Bone Marrow Transplant. 2010;45(5):862\u201371.","journal-title":"Bone Marrow Transplant"},{"key":"837_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1371\/journal.pone.0027351","volume":"6","author":"C Brehm","year":"2011","unstructured":"Brehm C, Huenecke S, Quaiser A, Esser R, Bremm M, Kloess S, et al. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I\/II study. PLoS One. 2011;6:11.","journal-title":"PLoS One"},{"issue":"8","key":"837_CR19","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","volume":"24","author":"B Andreas","year":"2018","unstructured":"\u2022 Andreas B, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, et al. Complete remission with reduction of high-risk clones following Haploidentical NK cell therapy against MDS and AML. Clin Cancer Res epub. 2018;24(8):1834\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3196 . This paper demonstrates the role of NK cells can play as a bridge to transplant for high risk AML\/MDS.","journal-title":"Clin Cancer Res epub"},{"issue":"11","key":"837_CR20","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/leu.2012.167","volume":"26","author":"MM Pfeiffer","year":"2012","unstructured":"Pfeiffer MM, Schumm M, Muller I, Handretinger R, Lang P. Il-15 stimulated CD3\/CD19 depleted stem cell boosts in relapsed pediatric patients after haploidentical SCT. Leukemia. 2012;26(11):2435\u20139. https:\/\/doi.org\/10.1038\/leu.2012.167 Epub 2012 Jun 22.","journal-title":"Leukemia."},{"key":"837_CR21","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/jcmm.12810","volume":"20","author":"A Romanski","year":"2016","unstructured":"\u2022 Romanski A, et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med. 2016;20:1287\u201394. https:\/\/doi.org\/10.1111\/jcmm.12810 . NK cells can be used for CAR therapy.","journal-title":"J Cell Mol Med"},{"issue":"357","key":"837_CR22","doi-asserted-by":"publisher","first-page":"357ral23","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Science Translational Medicine. 2016;8(357):357ral23. https:\/\/doi.org\/10.1126\/scitranslmed.aaf2341 .","journal-title":"Science Translational Medicine"},{"issue":"1","key":"837_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","volume":"33","author":"KC Conlon","year":"2015","unstructured":"\u2022 Conlon KC, Lugli E, Welles HC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8T cells, and cytokine production during first in human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015;33(1):74\u201382. https:\/\/doi.org\/10.1200\/JCO.2014.57.3329 . In an attempt to augment the effect of NK cells, Interleukin-15 shows benefit without the unwanted effect of stimulating T regulatory cells.","journal-title":"J Clin Oncol"},{"issue":"35","key":"837_CR24","doi-asserted-by":"crossref","first-page":"56219","DOI":"10.18632\/oncotarget.11019","volume":"7","author":"KH Chen","year":"2016","unstructured":"Chen KH, Wada M, Firor AE, Pinz KG, Jares A, Liu H, et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget. 2016 Aug 30;7(35):56219\u201332.","journal-title":"Oncotarget"},{"key":"837_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40425-019-0564-6","volume":"7","author":"R Nguyen","year":"2019","unstructured":"Nguyen R, Huiyan W, Stanley P, Hiroto I, Raul CR, David C, et al. A phase II clinical trial of adoptive transferred of haploidentical natural killer cells as consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer. 2019;7:81. https:\/\/doi.org\/10.1186\/s40425-019-0564-6 .","journal-title":"J Immunother Cancer"},{"key":"837_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Salvodo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19 targeted CAR show long term persistence and potent antitumor activity. Leukemia. 2018;32:520\u201331. https:\/\/doi.org\/10.1038\/leu.2017.226 .","journal-title":"Leukemia"},{"issue":"3","key":"837_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00262-007-0383-3","volume":"57","author":"T Muller","year":"2008","unstructured":"Muller T, Uherek C, Maki G, Chow KU, Schimp A, Klingemann HG. TonnT, Wels WS. Cancer Immunol Immunother. 2008 March;57(3):411\u201323.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"837_CR28","doi-asserted-by":"publisher","first-page":"e0123416","DOI":"10.1371\/journal.pone.0123416","volume":"10","author":"PD Kottardis","year":"2015","unstructured":"Kottardis PD, North J, Tsirogianni M, Marden C, Samuel ER, Jide-Banwo S, et al. Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial. PLoS One. 2015;10(6):e0123416.","journal-title":"PLoS One"},{"issue":"2","key":"837_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","volume":"8","author":"H Jiang","year":"2014","unstructured":"Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014;8(2):297\u2013310.","journal-title":"Mol Oncol"},{"key":"837_CR30","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28147","volume":"3","author":"G Klingemann","year":"2014","unstructured":"Klingemann G. Are natural killer cells superior CAR drivers? OncoImmunology. 2014;3:e28147.","journal-title":"OncoImmunology"},{"key":"837_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fphar.2015.00021","volume":"6","author":"W Glienke","year":"2015","unstructured":"Glienke W. Advantages and applications of CAR \u2013 expressing natural killer cells. Front Pharmacol. 2015;6:21.","journal-title":"Front Pharmacol"},{"issue":"2","key":"837_CR32","doi-asserted-by":"publisher","first-page":"181\u2013192.e5","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"\u2022 Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell. 2018;23(2):181\u2013192.e5. https:\/\/doi.org\/10.1016\/j.stem.2018.06.002 Epub 2018 Jun 28. Human iPSC- derived NK cells can be an alternative source and can be used for CAR therapy.","journal-title":"Cell Stem Cell"},{"issue":"9","key":"837_CR33","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1172\/JCI62749","volume":"122","author":"N Tarek","year":"2012","unstructured":"Tarek N, et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Investig. 2012;122(9):3260\u201370.","journal-title":"J Clin Investig"},{"issue":"23","key":"837_CR34","doi-asserted-by":"publisher","first-page":"9554","DOI":"10.1158\/0008-5472.CAN-10-2211","volume":"70","author":"DC Delgado","year":"2010","unstructured":"Delgado DC, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Research. 2010;70(23):9554\u201361.","journal-title":"Cancer Research"},{"issue":"21","key":"837_CR35","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1200\/JCO.2015.64.9558","volume":"34","author":"CJ Forlenza","year":"2016","unstructured":"Forlenza CJ, et al. KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. J Clin Oncol. 2016;34(21):2443\u201351.","journal-title":"J Clin Oncol"},{"issue":"1","key":"837_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-17-1767","volume":"24","author":"A Erbe","year":"2018","unstructured":"Erbe A, Wang W, Carmichael L, Kim KM, Mendonca E, Song Y, et al. Neuroblastoma KIR and KIR-ligand genotypes influence clinical outcome for Dinutuximab based immunotherapy: COG report. Clin Cancer Res. 2018;24(1):189\u201396.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"837_CR37","doi-asserted-by":"publisher","first-page":"e1461305","DOI":"10.1080\/2162402X.2018.1461305","volume":"7","author":"S Modak","year":"2018","unstructured":"Modak S, Le Luduec JB, Cheung IY, Goldman DA, Ostrovnaya I, Doubrovina E, et al. Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. OncoImmunology. 2018;7(8):e1461305. https:\/\/doi.org\/10.1080\/2162402X.2018.1461305 .","journal-title":"OncoImmunology"},{"key":"837_CR38","doi-asserted-by":"publisher","first-page":"11e1235108","DOI":"10.1080\/2162402X.2016.1235108","volume":"5","author":"N Siebert","year":"2016","unstructured":"\u2022 Siebert N, et al. Neuroblastoma patients with high affinity FCGR2A, 3A and stimulatory KIR2DS2 treated by long term infusion of anti GD2 antibody ch14.18\/ CHO show higher ADCC levels and improved event free survival. Oncoimmunology. 2016;5:11e1235108. https:\/\/doi.org\/10.1080\/2162402X.2016.1235108 . Donor and patient characteristics can be used to determine or predict the response to NK cell treatment and use of anti GD2.","journal-title":"Oncoimmunology"},{"issue":"5","key":"837_CR39","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bbmt.2017.12.805","volume":"24","author":"T Illhardt","year":"2018","unstructured":"Illhardt T, Toporski J, Feuchtinger T, Turkiewicz D, Teltschik HM, Ebinger M, et al. Haploidentical Stem Cell Transplantation for Refractory\/Relapsed Neuroblastoma. Biol Blood Marrow Transplant. 2018;24(5):1005\u201312. https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.805 .","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"837_CR40","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.bbmt.2017.07.011","volume":"23","author":"AC Talleur","year":"2017","unstructured":"Talleur AC, et al. Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan\/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant. 2017;23(11):1910\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"837_CR41","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/1078-0432.CCR-16-1743","volume":"23","author":"HC Tran","year":"2017","unstructured":"\u2022 Tran HC, Wan Z, Sheard MA, Sun J, Jackson JR, Malvar J, et al. TGFbetaR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells. Clin Cancer Res. 2017;23(3):804\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1743 . Overcoming factors that can prevent response to Anti GD2 and Nk cell therapy is important in treating patients with high risk neuroblastoma.","journal-title":"Clin Cancer Res"},{"key":"837_CR42","doi-asserted-by":"crossref","unstructured":"Burga RA, Williams E, Yvon E, Fernandex R, Russell C,Cruz Y and Bollard C. Generating suppression-resistant natural killer cells as an enhanced immunotherapeutic for neuroblastoma J Immunol May 1, 2018, 200 (1 Supplement) 179.6.","DOI":"10.4049\/jimmunol.200.Supp.179.6"},{"issue":"15","key":"837_CR43","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-10-0735","volume":"16","author":"D Cho","year":"2010","unstructured":"Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors. Clin Cancer Res. 2010;16(15):3901\u20139.","journal-title":"Clin Cancer Res"},{"key":"837_CR44","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1038\/bjc.2013.630","volume":"109","author":"U Thiel","year":"2013","unstructured":"Thiel U, Koscielniak E, Blaeschke F, Grunewald TG, Badoglio M, Diaz MA, et al. Solid Tumour Working Party and the Paediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment. Br J Cancer. 2013;109:2523\u201332. https:\/\/doi.org\/10.1038\/bjc.2013.630 .","journal-title":"Br J Cancer"},{"issue":"6","key":"837_CR45","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1055\/s-2006-942256","volume":"218","author":"P Lang","year":"2006","unstructured":"Lang P, Pfeiffer M, M\u00fcller I, Schumm M, Ebinger M, Koscielniak E, et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr. 2006;218(6):321\u20136.","journal-title":"Klin Padiatr"},{"issue":"1","key":"837_CR46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/pbc.21955","volume":"53","author":"A P\u00e9rez-Mart\u00ednez","year":"2009","unstructured":"P\u00e9rez-Mart\u00ednez A, Leung W, Mu\u00f1oz E, Iyengar R, Ram\u00edrez M, Vicario JL, et al. KIR\u2013HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer. 2009;53(1):120\u20134. https:\/\/doi.org\/10.1002\/pbc.21955 .","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"837_CR47","doi-asserted-by":"publisher","first-page":"882\u2013891. e1","DOI":"10.1016\/j.exphem.2012.07.004","volume":"40","author":"A Perez-Martinez","year":"2012","unstructured":"Perez-Martinez A, Prada Vicente I, Fern\u00e1ndez L, Gonz\u00e1lez-Vicent M, Valent\u00edn J, Mart\u00edn R, et al. Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Exp Hematol. 2012;40(11):882\u2013891. e1. https:\/\/doi.org\/10.1016\/j.exphem.2012.07.004 Epub 2012 Jul 4.","journal-title":"Exp Hematol"},{"key":"837_CR48","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","volume":"2012","author":"D Loo","year":"1814","unstructured":"Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, et al. Development of an fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 1814;2012:3834\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0715 .","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"837_CR49","first-page":"TPS2596-TPS2596","volume":"35","author":"K Desantes","year":"2017","unstructured":"Desantes K, John MM, McDowell K, Mackall C, Shankar S, Vasselli J, et al. A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors. ASCO Abstr J Clin Oncol. 2017;35(15_suppl):TPS2596-TPS2596.","journal-title":"ASCO Abstr J Clin Oncol"},{"key":"837_CR50","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fimmu.2017.00202","volume":"8","author":"K Fischer","year":"2017","unstructured":"Fischer K, Tognarelli S, Roesler S, Boedicker C, Schubert R, Steinle A, et al. The Smac Mimetic BV6 Improves NK Cell-Mediated Killing of Rhabdomyosarcoma Cells by Simultaneously Targeting Tumor and Effector Cells. Front Immunol. 2017;8:202. https:\/\/doi.org\/10.3389\/fimmu.2017.00202 eCollection 2017.","journal-title":"Front Immunol"},{"issue":"12","key":"837_CR51","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1080\/15384047.2016.1250047","volume":"17","author":"K Haberthur","year":"2016","unstructured":"Haberthur K, Brennan K, Hoglund V, Balcaitis S, Chinn H, Davis A, et al. NKG2D ligand expression in pediatric brain tumors. Cancer Biol Ther. 2016;17(12):1253\u201365. https:\/\/doi.org\/10.1080\/15384047.2016.1250047 Epub 2016 Nov 11.","journal-title":"Cancer Biol Ther"},{"key":"837_CR52","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11060-019-03091-5","volume":"142","author":"BA Kennis","year":"2019","unstructured":"Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, et al. Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neuro-Oncol. 2019;142:395\u2013407. https:\/\/doi.org\/10.1007\/s11060-019-03091-5 .","journal-title":"J Neuro-Oncol"},{"issue":"3","key":"837_CR53","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","volume":"7","author":"R Parihar","year":"2019","unstructured":"\u2022 Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, et al. NK Cells Expressing a Chimeric Activating Receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol Res. 2019;7(3):363\u201375. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0572 Epub 2019 Jan 16. CAR therapy has been less successful in solid tumors due to microenvironment with MDSCs playing a role.","journal-title":"Cancer Immunol Res"},{"issue":"24","key":"837_CR54","doi-asserted-by":"publisher","first-page":"7059","DOI":"10.1158\/0008-5472.CAN-17-1032","volume":"77","author":"O Isabel","year":"2017","unstructured":"Isabel O, Ducimetriere L, Marinho J, Kulig P, Burkhard B, Tugues S. Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade. Cancer Res. 2017;77(24):7059\u201371. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1032 .","journal-title":"Cancer Res"},{"key":"837_CR55","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/cancers11030277","volume":"11","author":"L Clar Kim","year":"2019","unstructured":"Clar Kim L, Hinterleitner C, Schneider P, Salih HR, Maurer S. Inhibition of NK reactivity against solid tumors by platelet-derived RANKL. Cancers. 2019;11:277. https:\/\/doi.org\/10.3390\/cancers11030277 .","journal-title":"Cancers"},{"key":"837_CR56","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrd4506","volume":"14","author":"RW Childs","year":"2015","unstructured":"Childs RW. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer, the force awakens. Nat Drug Discov. 2015;14:487\u201398. https:\/\/doi.org\/10.1038\/nrd4506 .","journal-title":"Nat Drug Discov"},{"issue":"7","key":"837_CR57","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9 P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti NKG2A mAb is a checkpoint inhibitor that promotes anti tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731. https:\/\/doi.org\/10.1016\/j.cell.2018.10.014 Epub 2018 Nov 29.","journal-title":"Cell"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0837-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-019-0837-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0837-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T02:07:07Z","timestamp":1695175627000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-019-0837-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["837"],"URL":"https:\/\/doi.org\/10.1007\/s11912-019-0837-8","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]},"assertion":[{"value":"10 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Miriam Santiago Kimpo, Bernice Oh, and Shawn Lee declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"93"}}